Signaling pathways of EBV-induced oncogenesis

Table 1 Clinical and experimental therapeutic strategies for EBV-induced cancer

Therapy/drug	Target	Function	Cancer/disease	References
CTL	LMP1/LMP2	Stimulates LMP-specific T cell expansion	NK/T cell lymphoma	[82,83,84]
TCR	EBNA1/LMP1/ LMP2A	Stimulate and expand EBV-specific CD8 + T cells in patients	Progressive multiple sclerosis	[85]
Recombinant vaccinia virus	ENBA1/LMP2	Promote the production of EBNA1/LMP2 antibodies	Nasopharyngeal carcinoma	[87]
DNAzyme	LMP1	Targeted degradation of LMP1 mRNA	Nasopharyngeal carcinoma	[88]
Fedratinib, AZD1480 and LY294002	JAK2, PI3K and mTOR	Inhibit the expression of PD-L1 and restore immune surveillance	Gastric cancer	[89]
IMD-0354	NF-κB	Inhibit proliferation and increase apoptosis	NK/T cell lymphoma	[90]
AT13387	Hsp90	Inhibit the expression of AKT/p-AKT, restore the function of p27 and inhibit cancer cell proliferation	Nasopharyngeal carcinoma	[92]

ISSN: 1475-2867